GRADE table 2(Question 2): Among women of reproductive age using combined hormonal contraception (CHC), are women with known dyslipidaemias without other known cardiovascular risk factors at increased risk for ATE, VTE or pancreatitis compared to women without known dyslipidaemias? (Indirect evidence)

OutcomeType and number of studies
(number of participants)		LimitationsInconsistencyImprecisionIndirectnessOther factorsQualityEstimate of effect
Women with hyperlipidaemia vs no hyperlipidaemia prescribed combined oral contraceptives
Deep vein thrombosis (DVT) and pulmonary embolism (PE)1 cohort study
(n=329 995)		Very serious limitations
(1 poor)		Cannot determine
(1 study)		No serious imprecisionSerious indirectness
(not COC use vs non-use)		NoneVery low8.51 vs 6.14 per 10 000 woman-years, IRR 1.39 (95% CI 1.04–1.85)

CI: confidence interval; IRR: incidence rate ratio.

From: I, Development of the Medical eligibility criteria for contraceptive use, fifth edition

Cover of Medical Eligibility Criteria for Contraceptive Use
Medical Eligibility Criteria for Contraceptive Use. 5th edition.
Copyright © World Health Organization 2015.

All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: tni.ohw@sredrokoob).

Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html).

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.